These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

169 related items for PubMed ID: 32830561

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2. Nivolumab-induced autoimmune diabetes mellitus presenting as diabetic ketoacidosis in a patient with metastatic lung cancer.
    Godwin JL, Jaggi S, Sirisena I, Sharda P, Rao AD, Mehra R, Veloski C.
    J Immunother Cancer; 2017; 5():40. PubMed ID: 28515940
    [Abstract] [Full Text] [Related]

  • 3. A Severe Case of Diabetic Ketoacidosis and New-Onset Type 1 Diabetes Mellitus Associated with Anti-Glutamic Acid Decarboxylase Antibodies Following Immunotherapy with Pembrolizumab.
    Kedzior SK, Jacknin G, Hudler A, Mueller SW, Kiser TH.
    Am J Case Rep; 2021 Jun 29; 22():e931702. PubMed ID: 34185763
    [Abstract] [Full Text] [Related]

  • 4. Diabetic ketoacidosis induced by a single dose of pembrolizumab.
    Maamari J, Yeung SJ, Chaftari PS.
    Am J Emerg Med; 2019 Feb 29; 37(2):376.e1-376.e2. PubMed ID: 30361152
    [Abstract] [Full Text] [Related]

  • 5. Programmed Cell Death-1 Inhibitor-Induced Type 1 Diabetes Mellitus.
    Clotman K, Janssens K, Specenier P, Weets I, De Block CEM.
    J Clin Endocrinol Metab; 2018 Sep 01; 103(9):3144-3154. PubMed ID: 29955867
    [Abstract] [Full Text] [Related]

  • 6. Pembrolizumab-induced type 1 diabetes.
    Maia A, Soares DM, Azevedo S, Pereira T, Amaral C.
    J Oncol Pharm Pract; 2024 Sep 01; 30(6):1118-1121. PubMed ID: 38766907
    [Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10. Immune Checkpoint Inhibitor-Induced Diabetic Ketoacidosis: A Report of Four Cases and Literature Review.
    Hong AR, Yoon JH, Kim HK, Kang HC.
    Front Endocrinol (Lausanne); 2020 Sep 01; 11():14. PubMed ID: 32047478
    [Abstract] [Full Text] [Related]

  • 11. Combined checkpoint inhibitor therapy causing diabetic ketoacidosis in metastatic melanoma.
    Changizzadeh PN, Mukkamalla SKR, Armenio VA.
    J Immunother Cancer; 2017 Dec 19; 5(1):97. PubMed ID: 29254501
    [Abstract] [Full Text] [Related]

  • 12. Severe Oral Mucositis: A Rare Adverse Event of Pembrolizumab.
    Lederhandler MH, Ho A, Brinster N, Ho RS, Liebman TN, Lo Sicco K.
    J Drugs Dermatol; 2018 Jul 01; 17(7):807-809. PubMed ID: 30005106
    [Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14. Diabetic Ketoacidosis as an Immune-related Adverse Event from Pembrolizumab in Non-Small Cell Lung Cancer.
    Leonardi GC, Oxnard GR, Haas A, Lang JP, Williams JS, Awad MM.
    J Immunother; 2017 Jul 01; 40(6):249-251. PubMed ID: 28557813
    [Abstract] [Full Text] [Related]

  • 15. Anti-PD-1 pembrolizumab induced autoimmune diabetes in Chinese patient: A case report.
    Li S, Zhang Y, Sun Z, Hu J, Fang C.
    Medicine (Baltimore); 2018 Nov 01; 97(45):e12907. PubMed ID: 30407284
    [Abstract] [Full Text] [Related]

  • 16. Diabetic ketoacidosis following immunotherapy for lung cancer.
    Skorpen PK, Margull J.
    Tidsskr Nor Laegeforen; 2019 Feb 26; 139(4):. PubMed ID: 30808100
    [No Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18. Pembrolizumab-induced vitiligo in a patient with lung adenocarcinoma: A case report.
    Bulat V, Likic R, Bradic L, Speeckaert R, Azdajic MD.
    Br J Clin Pharmacol; 2021 Jun 26; 87(6):2614-2618. PubMed ID: 33217043
    [Abstract] [Full Text] [Related]

  • 19. Immune-Mediated Diabetes Mellitus, Diabetic Ketoacidosis, Enteritis, and Thrombotic Thrombocytopenic Purpura Presenting as Adverse Effects of Pembrolizumab Therapy.
    Luong B, Koch G, Trivedi K, Ramachandran K.
    Am J Ther; 2021 Jun 26; 31(4):e474-e475. PubMed ID: 38976534
    [No Abstract] [Full Text] [Related]

  • 20. Rapid onset type-1 diabetes and diabetic ketoacidosis secondary to nivolumab immunotherapy: a review of existing literature.
    Abdullah HMA, Elnair R, Khan UI, Omar M, Morey-Vargas OL.
    BMJ Case Rep; 2019 Aug 26; 12(8):. PubMed ID: 31451458
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 9.